clinical trial · NCT07341100
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·phase2·not yet recruiting·n = 20
Ovarian Epithelial CancerSKB264Clarithromycin
brief summary
This is a multicenter, open-label study to evaluate the preliminary efficacy of SKB264 and the effect of clarithromycin on the PK of SKB264 in patients with ovarian epithelial cancer.
started
Jan 1, 2026
primary completion
Jan 1, 2028
completion
Jun 1, 2028
last updated
Jan 14, 2026
detailed description
Cycle 1 will be for drug-drug interaction (DDI) assessment. Thereafter, participants will receive SKB264 monotherapy.
official title
A Multicenter, Open-label Clinical Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin, a Potent CYP3A Inhibitor, on the Pharmacokinetics of SKB264 in Patients With Ovarian Epithelial Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol